Renzapride
Renzapride
Renzapride (/rɛnˈzæpraɪd/) is a gastroprokinetic agent and antiemetic which was developed by Alizyme plc but is no longer being actively researched. It acts as a 5-HT4 receptor agonist and 5-HT3 receptor antagonist. The drug was under development for the treatment of gastrointestinal disorders, but development was discontinued due to concerns about side effects and efficacy.
Etymology
The term "Renzapride" is derived from the combination of the words "ren" and "zapride". "Ren" is a prefix often used in the naming of drugs to indicate their action on the renal system, while "zapride" is a suffix used in the naming of drugs that act on the serotonin system.
Related Terms
- Gastroprokinetic agent: A type of drug that increases the movements or contractions of the stomach and intestines.
- Antiemetic: A drug that is effective against vomiting and nausea.
- 5-HT4 receptor: A type of receptor in the body that is activated by the neurotransmitter serotonin.
- 5-HT3 receptor: Another type of receptor in the body that is also activated by serotonin.
- Gastrointestinal: Relating to the stomach and the intestines.
See Also
External links
- Medical encyclopedia article on Renzapride
- Wikipedia's article - Renzapride
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski